Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Director Shareholding

9 Aug 2005 11:00

Flying Brands Limited09 August 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Flying Brands Limited 2) Name of director a) PI Fraser 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest In respect of P I Fraser 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Paul Ian Fraser 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) N/A 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Purchase of Ordinary shares, through exercising of share options granted on 14 October 2001. 7) Number of shares/amount of stock acquired 144,156 8) Percentage of issued class 0.55% 9) Number of shares/amount of stock disposed N/A 10) Percentage of issued class N/A 11) Class of security Ordinary Shares 12) Price per share 117.96p 13) Date of transaction 8 August 2005 14) Date company informed 8 August 2005 15) Total holding following this notification 5,790,875 16) Total percentage holding of issued class following this notification 21.97%If a director has been granted options by the company please complete the following boxes 17) Date of grant N/A 18) Period during which or date on which exercisable N/A 19) Total amount paid (if any) for grant of the option N/A 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification None 23) Any additional information 24) Name of contact and telephone number for queries Graham Norton 01376 57508125) Name and signature of authorised company official responsible for making this notification Graham Norton - Finance Director Date of Notification 8 August 2005 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.